Xu Cangcang, Zhang Huihui, Mu Lingli, Yang Xiaoping
Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Department of Pharmacy, School of Medicine, Hunan Normal University, Changsha, China.
Front Pharmacol. 2020 Oct 6;11:529881. doi: 10.3389/fphar.2020.529881. eCollection 2020.
Artemisinin and its derivatives have shown broad-spectrum antitumor activities and . Furthermore, outcomes from a limited number of clinical trials provide encouraging evidence for their excellent antitumor activities. However, some problems such as poor solubility, toxicity and controversial mechanisms of action hamper their use as effective antitumor agents in the clinic. In order to accelerate the use of ARTs in the clinic, researchers have recently developed novel therapeutic approaches including developing novel derivatives, manufacturing novel nano-formulations, and combining ARTs with other drugs for cancer therapy. The related mechanisms of action were explored. This review describes ARTs used to induce non-apoptotic cell death containing oncosis, autophagy, and ferroptosis. Moreover, it highlights the ARTs-caused effects on cancer metabolism, immunosuppression and cancer stem cells and discusses clinical trials of ARTs used to treat cancer. The review provides additional insight into the molecular mechanism of action of ARTs and their considerable clinical potential.
青蒿素及其衍生物已显示出广谱抗肿瘤活性。此外,有限数量的临床试验结果为其卓越的抗肿瘤活性提供了令人鼓舞的证据。然而,诸如溶解性差、毒性和作用机制存在争议等问题阻碍了它们在临床上作为有效的抗肿瘤药物使用。为了加速青蒿素类药物在临床上的应用,研究人员最近开发了新的治疗方法,包括开发新型衍生物、制备新型纳米制剂以及将青蒿素类药物与其他药物联合用于癌症治疗。对相关作用机制进行了探索。本综述描述了用于诱导包含胀亡、自噬和铁死亡在内的非凋亡性细胞死亡的青蒿素类药物。此外,它突出了青蒿素类药物对癌症代谢、免疫抑制和癌症干细胞的影响,并讨论了用于治疗癌症的青蒿素类药物的临床试验。该综述为青蒿素类药物的分子作用机制及其可观的临床潜力提供了更多见解。